DelveInsight’s, “Hepatitis B Virus Infection Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hepatitis B Virus (HBV) Infection pipeline landscape. It covers the Hepatitis B Virus Infection pipeline drug profiles, including Hepatitis B Virus Infection clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Hepatitis B Virus Infection pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Hepatitis B Virus Infection NDA approvals (if any), and product development activities comprising the technology, Hepatitis B Virus (HBV) Infection collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key Takeaways from the Hepatitis B Virus Infection Pipeline Insight Report
- DelveInsight’s Hepatitis B Virus Infection Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hepatitis B Virus Infection.
- The leading Hepatitis B Virus Infection Companies such as Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Nucorion Pharmaceuticals, Gilead Sciences Dong-A ST Co. Ltd., Assembly Biosciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals, and others
- Promising Hepatitis B Virus Infection Pipeline therapies such as EYP001a, VBR, AB-729, SOC NrtI, VIR-2218, NCO-48 Fumarate 4 mg, HB-AS02V, HBVAXPRO vaccine, ACH-126,443, Lamivudine, entecavir, FENDRIX, and others are under different phases of Hepatitis B Virus Infection clinical trials.
- The Hepatitis B Virus Infection Companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis B Virus (HBV) Infection R&D. The Hepatitis B Virus Infection pipeline therapies under development are focused on novel approaches to treat/improve Hepatitis B Virus (HBV) Infection.
To explore more information on the latest breakthroughs in the Hepatitis B Virus Infection Pipeline treatment landscape of the report, click here @ Hepatitis B Virus Infection Pipeline Outlook
Hepatitis B Virus Infection Overview
Hepatitis means inflammation of the liver. When the liver is inflamed or damaged, its function can be affected. Heavy alcohol use, toxins, some medications, and certain medical conditions can all cause hepatitis. However, hepatitis is often caused by a virus. In the United States, the most common hepatitis viruses are hepatitis A virus, hepatitis B virus, and hepatitis C virus.
Recent Breakthroughs of Hepatitis B Virus Infection Treatment Landscape
- AB-729 is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. AB-729 targets hepatocytes using the novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology. AB-729 is currently being evaluated in a Phase 2a randomized, open-label, proof-of-concept clinical trial in combination with ongoing standard-of-care nucleos(t)ide analog therapy and short courses of Peg-IFNα-2a in 40 patients with chronic HBV infection.
- ABI-H3733 (3733), is an investigational next-generation, highly potent core inhibitor. 3733 has demonstrated significantly increased potency against covalently closed circular DNA (cccDNA) formation and new virus production as compared to first-generation core inhibitors in preclinical studies. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Chronic Hepatitis B virus Infection.
- VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.
For further information, refer to the detailed Hepatitis B Virus Infection Unmet Needs, Hepatitis B Virus Infection Market Drivers, and Hepatitis B Virus Infection Market Barriers, click here for Hepatitis B Virus Infection Ongoing Clinical Trial Analysis
Hepatitis B Virus Infection Emerging Drugs Analysis Profile
- VIR 2218: Vir Biotechnology
VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.
- ABI H3733: Assembly Biosciences
ABI-H3733 (3733), is an investigational next-generation, highly potent core inhibitor. 3733 has demonstrated significantly increased potency against covalently closed circular DNA (cccDNA) formation and new virus production as compared to first-generation core inhibitors in preclinical studies. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Chronic Hepatitis B virus Infection.
- AB 729: Arbutus Biopharma
AB-729 is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. AB-729 targets hepatocytes using the novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology. AB-729 is currently being evaluated in a Phase 2a randomized, open-label, proof-of-concept clinical trial in combination with ongoing standard-of-care nucleos(t)ide analog therapy and short courses of Peg-IFNα-2a in 40 patients with chronic HBV infection.
Hepatitis B Virus Infection Pipeline Therapeutics Assessment
There are approx. 80+ key companies which are developing the therapies for Hepatitis B Virus (HBV) Infection. The companies which have their Hepatitis B Virus (HBV) Infection drug candidates in the most advanced stage, i.e. phase II include, Arbutus Biopharma.
Request a sample and discover the recent advances in Hepatitis B Virus Infection Ongoing Clinical Trial Analysis and Medications, click here @ Hepatitis B Virus Infection Treatment Landscape
Scope of the Hepatitis B Virus Infection Pipeline Report
- Coverage- Global
- Hepatitis B Virus Infection Companies- Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Nucorion Pharmaceuticals, Gilead Sciences Dong-A ST Co. Ltd., Assembly Biosciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals, and others
- Hepatitis B Virus Infection Pipeline therapies- EYP001a, VBR, AB-729, SOC NrtI, VIR-2218, NCO-48 Fumarate 4 mg, HB-AS02V, HBVAXPRO vaccine, ACH-126,443, Lamivudine, entecavir, FENDRIX, and others
- Hepatitis B Virus Infection Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Dive deep into rich insights for drugs for Hepatitis B Virus Infection Market Drivers and Hepatitis B Virus Infection Market Barriers, click here @ Hepatitis B Virus Infection Unmet Needs and Analyst Views
Table of Content
- Introduction
- Hepatitis B Virus Infection Executive Summary
- Hepatitis B Virus Infection: Overview
- Hepatitis B Virus Infection Pipeline Therapeutics
- Hepatitis B Virus Infection Therapeutic Assessment
- Hepatitis B Virus (HBV) Infection– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Mid Stage Products (Phase II)
- AB 729: Arbutus Biopharma
- Early Stage Products (Phase I)
- ABI H3733: Assembly Biosciences
- Preclinical and Discovery Stage Products
- Inactive Products
- Hepatitis B Virus Infection Key Companies
- Hepatitis B Virus Infection Key Products
- Hepatitis B Virus Infection – Unmet Needs
- Hepatitis B Virus Infection – Market Drivers and Barriers
- Hepatitis B Virus Infection – Future Perspectives and Conclusion
- Hepatitis B Virus Infection Analyst Views
- Hepatitis B Virus Infection Key Companies
- Appendix
Got Queries? Find out the related information on Hepatitis B Virus Infection Mergers and acquisitions, Hepatitis B Virus Infection Licensing Activities @ Hepatitis B Virus Infection Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/